Achievement of low level of disease activity with a dose of corticosteroids less than or equal to 5 mg (LLDAS5): a real-life study with anifrolumab on patients with systemic lupus erythematosus in Italy

Copyright © 2025 FULLCRO S.R.L. - TUTTI I DIRITTI RISERVATI
per contatti riguardanti lo Studio DAHLIA DAHLIA@fullcro.org